Quarterly report [Sections 13 or 15(d)]

Asset Acquisition - Schedule of Total Consideration, Assets and the Liabilities (Details)

v3.25.1
Asset Acquisition - Schedule of Total Consideration, Assets and the Liabilities (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Aug. 13, 2024
Mar. 28, 2024
Mar. 27, 2024
Apr. 30, 2024
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Common stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Conversion of stock, issuance(in shares) 6,585,314            
Almata Transaction And March 2024 Financing              
Asset Acquisition, Contingent Consideration [Line Items]              
Shares issuable in common stock (in shares)           349  
Series C Preferred Stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Shares converted (in shares)         200    
Series C Preferred Stock | Almata Transaction And March 2024 Financing              
Asset Acquisition, Contingent Consideration [Line Items]              
Shares issuable in common stock (in shares)     2,412        
Shares converted (in shares)     2,063        
AlmataBio Transaction              
Asset Acquisition, Contingent Consideration [Line Items]              
Stock consideration             $ 12,272
Milestone payment due upon close of private placement investment   $ 7,500   $ 7,500     7,500
Milestone payment due upon first patient dosed in a Phase 2 trial             5,000
Transaction costs             2,402
Total GAAP Purchase Price at Close             27,174
Acquired IPR&D             27,538
Cash             356
Accrued expenses and other current liabilities             (720)
Total net assets acquired and liabilities assumed             $ 27,174
Common stock shares issued (in shares)     171,605        
Shares issuable in common stock (in shares)     2,412        
Convertible preferred stock, shares issued upon conversion (in shares)     2,412,000        
Closing stock price (in dollars per share)     $ 4.75        
AlmataBio Transaction | Common stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Conversion of stock, issuance(in shares)     2,062,930